Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Oncolytics announced continued clinical and operational progress for the REO 033 program evaluating pelareorep in second-line RAS-mutant mCRC.